Du är här

2015-08-24

Hofseth Biocare ASA : Signs contract on ProGo (TM) with Fraser Cameron Healthcare in the United Kingdom

Hofseth BioCare ASA (HBC) have today signed a contract with Fraser Cameron Healthcare Ltd. (FCH) on shipments of HBCs salmon protein hydrolysate ProGo (TM). The contract extends over 3 years and will be used for a new product for weight control in the United Kingdom. The agreement is entered into via HBCs distributor, Aceto Health Ingredients. First deliveries will take place in the 4th quarter of 2015 and the total contract value over three years, is estimated to MNOK 24.
- Our distributor in the EU, Aceto Health Ingredients, have since our distribution agreement was signed, presented our protein in several countries in the European Union and we are now beginning to see the results of this cooperation. This is good news and a strategic important deal in an exciting market, says VP Global Sales Ole Arne Eiksund in HBC.
HBCs most recent clinical study on ProGo (TM) shows that our protein hydrolysates have good characteristics for weight control and potential BMI reduction. Fraser Cameron Healthcare have in addition to our studies also carried out their own tests. Based on these results, they have now decided to move ahead and launch a weight-control product based on our ProGo(TM).
For more information, please contact:

Ole Arne Eiksund, VP Global Sales Hofseth BioCare ASA
Mobile: + 47 90843944
Epost:oae@hofsethbiocare.no
Jon Olav Ødegård, CEO Hofseth BioCare ASA

Mobile: +47 93632966
Email:joo@h-bc.no
About Fraser Cameron Healthcare Ltd.:

Fraser Cameron Healthcare Ltd is a UK based healthcare company focused on developing high-quality, effective, clinically-proven healthcare products that support consumers in improving their health and wellbeing.
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. Hofseth BioCare`s objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hofseth Biocare ASA via Globenewswire

HUG#1947209

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.